FELIQS Announces $9 Million Series A Financing to Advance FLQ-101 Clinical Program for Retinopathy of Prematurity

FELIQS secures $9m for FLQ-101 to prevent retinopathy of prematurity

FELIQS has concluded a $9m Series A funding round, a significant step towards advancing the FLQ-101 clinical programme for ROP.The post FELIQS secures $9m for FLQ-101 to prevent retinopathy of prematurity appeared first on Clinical Trials Arena.

FELIQS Secures $9 Million Series A Funding to Advance FLQ-101 for Retinopathy of Prematurity

FELIQS Corporation, a biotechnology firm specializing in innovative treatments for rare pediatric retinal diseases, has successfully closed a $9 million Series A financing round. This funding, co-led by a prominent American pharmaceutical company and Beyond Next Ventures Inc., with contributions from the Japan Science and Technology Agency and existing investors, marks a pivotal moment in the development of FLQ-101. FLQ-101 is FELIQS’s lead cand…

Feliqs Secures $9 Million Series A to Advance FLQ-101 Clinical Trial for Retinopathy of Prematurity

Feliqs Corp. announced the successful completion of a $9 million Series A financing round to advance the company's lead investigational therapy, FLQ-101, into clinical development. Designed as a once-daily oral or intravenous formulation, FLQ-101 aims to prevent retinopathy of prematurity (ROP) by promoting physiological retinal vascularization and protecting against both inflammation and pathological neovascularization. The company’s phase 1b/2…

FELIQS Announces $9 Million Series A Financing to Advance FLQ-101 Clinical Program for Retinopathy of Prematurity

Fukuoka, Japan and New York, New York--(Newsfile Corp. - July 1, 2025) - FELIQS Corporation ('FELIQS'), a biotechnology company developing